Abstract:Mitophagy defects lead to increased mitochondrial ROS in cancer cells. On the one hand, the increased mitochondrial ROS promotes tumor metastasis, and on the other hand, mitochondrial ROS accelerates the production of tumor lipid peroxidation under ferroptosis induction therapy. This makes tumors with mitophagy defects acquire the ability to progress malignantly while also showing ferroptosis vulnerability. The identification of ferroptosis‐sensitive cancers is critical for the application of ferroptosis‐inducing therapies in cancer therapy. Here, patient‐derived organoid screening models of colorectal cancer are established to identify tumors that are sensitive to ferroptosis‐inducing therapy. This study discovers that patient‐derived tumors characterized by mitophagy deficiency are hypersensitive to ferroptosis‐inducing therapies. Mechanistically, a novel negative feedback regulatory pathway of lipid peroxidation is identified, which is one of the important intrinsic anti‐ferroptosis mechanisms of cancer cells. Lipid peroxidation‐mediated endoplasmic reticulum stress transcriptionally upregulates Parkin to promote mitophagy through ATF4. Mitophagy limits the generation of lipid peroxidation products and subsequently inhibits ferroptosis by inhibiting the accumulation of mitochondrial ROS. Mitophagy‐deficient tumors lack this anti‐ferroptotic mechanism, unleashing the generation of lipid peroxidation and potent ferroptotic cell death induced by erastin, RSL3, cysteine deprivation, radiotherapy, and immunotherapy. More importantly, ferroptosis‐inducing therapy selectively inhibits the growth and distant metastasis of mitophagy‐deficient tumors in vivo. In summary, patient‐derived organoids of colorectal cancer patients for screening ferroptosis‐sensitive tumors are established, providing a paradigm for identifying that patient‐derived tumors are sensitive to ferroptosis‐inducing therapies. This study concludes that mitophagy‐deficient tumors are vulnerable to ferroptosis induction, which may lead to the development of new therapeutic strategies for tumors deficient in mitophagy.

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade

Organelle Synergy Unleashed: Modulating Mitochondrial-Endoplasmic Reticulum Contacts with a Self-Assembled Prodrug Amplifies Ferroptosis for Innovative Cancer Therapy

Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells

Cholesterol Depletion-Enhanced Ferroptosis and Immunotherapy via Engineered Nanozyme

Susceptibility of Mitophagy‐Deficient Tumors to Ferroptosis Induction by Relieving the Suppression of Lipid Peroxidation

A Metabolic Intervention Strategy for Enhanced Ferroptosis/cuproptosis Activation and Boosted Anti-Tumor Immunity

Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts

The Mutual Regulatory Role of Ferroptosis and Immunotherapy in Anti-tumor Therapy

Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis Via Synergistic Repression of SLC7A11.

Ultrathin Clay Nanoparticles‐Mediated Mutual Reinforcement of Ferroptosis and Cancer Immunotherapy

Nonferrous Ferroptosis Inducer Manganese Molybdate Nanoparticles to Enhance Tumor Immunotherapy

Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism

Ferroptosis crosstalk in anti-tumor immunotherapy: molecular mechanisms, tumor microenvironment, application prospects

CD8+ T Cells Regulate Tumor Ferroptosis by Targeting the System Xc− During Cancer Immunotherapy

Nanomedicine-mediated ferroptosis targeting strategies for synergistic cancer therapy.

Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma

SLC43A2 and NFκB signaling pathway regulate methionine/cystine restriction-induced ferroptosis in esophageal squamous cell carcinoma via a feedback loop

Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer

Enhanced ferroptosis therapy with a "nano-destructor" by disrupting intracellular redox and iron homeostasis

Multimodal synergistic ferroptosis cancer therapy

Multimodal Enhancement of Ferroptosis for Synergistic Cascade Colorectal Cancer Therapy